Mr. James Passin reports

BIOVAXYS ANNOUNCES APPLICATION FOR MANAGEMENT CEASE TRADE ORDER

Biovaxys Technology Corp. was unable to file its annual financial statements, management's discussion and analysis, and the required certifications for the year ended Oct. 31, 2025 (the annual filings), on or before the prescribed filing deadline of Feb. 28, 2026 (the annual filing deadline).

The company and the auditor have been diligently working to complete the annual filings, however, the company was not able to make the required filings by the annual filing deadline. The primary contributing factor to the delay was a late start to the audit as a result of the company making changes to its accounting systems and processes. The company believes that the audit will be completed by April 28, 2026, with the annual filings to be completed as soon as possible thereafter.

As a result, the company filed an application to the British Columbia Securities Commission to approve a temporary management cease trade order (MCTO) under National Policy 12-203 -- Management Cease Trade Orders. The MCTO was granted, effective March 3, 2026, prohibiting trading in securities of the company by the chief executive officer of the company, James Passin, and chief financial officer of the company, Christopher Cherry.

The company expects to file the annual filings by April 28, 2026. The MCTO will be in effect until the annual filings are filed. The company confirms that it will comply with the alternative information guidelines required by NP 12-203 so long as the annual filings are outstanding.

The guidelines, among other things, require the company to issue biweekly default status reports, in the form of news releases, for so long as the annual filings have not been filed.

About Biovaxys Technology Corp.

Biovaxys Technology, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix tumour cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy and other immunological diseases. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust and persistent immune response. The company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX platform, in phase IIB clinical development for advanced relapsed-refractory diffuse large B cell lymphoma (DLBCL) and platinum-resistant ovarian cancer. MVP-S delivers antigenic peptides from the survivin family, a set of well-recognized cancer antigens commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumour immune response. Biovaxys is also developing DPX+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX-RSV for respiratory syncytial virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix neoantigen tumour cell construct platform for refractive late-stage ovarian cancer.

Biovaxys common shares are listed on the Canadian Securities Exchange under the stock symbol BIOV and trade on the Frankfurt Bourse (FSE: 5LB) and in the United States on the OTC Markets (OTCQB: BVAXF).

We seek Safe Harbor.